Drugs / EMP-123
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00850668 | Oct 2009 → Oct 2010 | food allergy | Allertein Therapeutics, LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EMP-123 | “a study product that contains recombinant modified peanut proteins (EMP-123)” NCT00850668 ↗ |
| Modality | Vaccine | “EMP-123 is designed to act as an allergy vaccine” NCT00850668 ↗ |
| Route | Rectal | “This study will evaluate the safety of a rectally administered product, EMP-123” NCT00850668 ↗ |